Alector Q4 net loss narrows to $2.1M; latozinemab Phase 3 data expected Q4 2025

Alector, Inc.

2024-FY EPS reported -$1.23 revenue$100,600,000

Q4 2024 net loss $2.1M ($0.02 loss per share) vs $41.4M loss ($0.49 loss) in Q4 2023, revenue $54.2M vs $15.2M.
Cash, cash equivalents and investments $413.4M, expected to fund operations through 2026.
Topline data from pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN anticipated by Q4 2025.
Enrollment in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer's expected to complete by mid-2025.
2025 guidance: collaboration revenue $5-15M, R&D expense $175-185M, G&A $55-65M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.